Newborn Screening and LSDs in the Neonatal Period
Lysosomal & Rare Disorders Research & Treatment Center
GRIDS-2023
Newborn Screening and LDs in the Neonatal Period
January 30, 2024 – January 30, 2025
Estimated time to complete: 1.75 hours
NO LONGER AVAILABLE FOR CREDIT
Continuing Education Information
This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.
Speakers
Can Ficicioglu, MD, PhD
Children’s Hospital of Philadelphia, Philadelphia, PA
Orna Staretz-Chacham, MD
Soroka University Medical Center, Beer-Sheva, Israel
Debra Regier, MD
Children’s National, Washington DC
David Kronn, MD
New York Medical College, Valhalla, NY
Disclosures
AffinityCE staff, LDRTC staff, CheckRare CE staff, planners, and reviewers, have no relevant financial interests to disclose. All faculty disclosures are listed below and will be stated prior to the start of each session.
Faculty disclosures
Can Ficicioglu, MD, PhD
Advisor/Consultant: Horizon Therapeutics, Travere, Sanofi Genzyme, Takeda, Avrobio, Acer and Chiesi.
Research grants: Travere, Passage Bio, Regenxbio, Sanofi Genzyme, Takeda, JNANA, Synlogic, Denali and JCR.
Orna Staretz-Chacham, MD
No disclosures
Debra Regier, MD
Educational grant: Takeda, Travere.
David Kronn, MD
Advisory Board: AskBio
Research grant: Sanofi
Speaker’s bureau: Sanofi
Mitigation of Relevant Financial Relationships
AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships reported have been mitigated prior to the commencement of the activity through peer review of content by non-conflicted reviewers.
Learning Objectives
At the end of this activity, participants should be able to address one or more of the following:
- Describe how a disease get on newborn screening panels
- Describe best practices to add diseases to newborn screening panels
- Describe best practices to interpret newborn screening results
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 1.75 hours of continuing nursing education credit.
Nurse Practitioners
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.
Genetic Counselors
Category 2 CEU
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.
Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
Commercial Support
Educational grant support for GRIDS 2023 provided by Amicus, Chiesi, Sanofi, Lilly, and Takeda.
Participation Costs
There is no cost to participate in this activity.
CME Inquiries
For all CME policy-related inquiries, please contact us at [email protected].
Send customer support requests to [email protected].
